[go: up one dir, main page]

ES2186484B1 - Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. - Google Patents

Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.

Info

Publication number
ES2186484B1
ES2186484B1 ES200002447A ES200002447A ES2186484B1 ES 2186484 B1 ES2186484 B1 ES 2186484B1 ES 200002447 A ES200002447 A ES 200002447A ES 200002447 A ES200002447 A ES 200002447A ES 2186484 B1 ES2186484 B1 ES 2186484B1
Authority
ES
Spain
Prior art keywords
treatment
tumors
evil
cancer drugs
liposomes encapsulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002447A
Other languages
English (en)
Other versions
ES2186484A1 (es
Inventor
Antonio Parente Dueña
Ferran Pons Labiez
Angel Fabra Fres
M. Dolores Polo Trasancos
Josep Garces Garces
Francesca Reig Isart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002447A priority Critical patent/ES2186484B1/es
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to CA2425271A priority patent/CA2425271C/en
Priority to US10/398,627 priority patent/US7153490B2/en
Priority to AU9190401A priority patent/AU9190401A/xx
Priority to AT01972111T priority patent/ATE318582T1/de
Priority to AU2001291904A priority patent/AU2001291904C1/en
Priority to PT01972111T priority patent/PT1325739E/pt
Priority to PCT/ES2001/000367 priority patent/WO2002030397A1/es
Priority to DE60117583T priority patent/DE60117583T2/de
Priority to BR0113552-0A priority patent/BR0113552A/pt
Priority to JP2002533840A priority patent/JP4286535B2/ja
Priority to DK01972111T priority patent/DK1325739T3/da
Priority to ES01972111T priority patent/ES2259674T3/es
Priority to MXPA03003125A priority patent/MXPA03003125A/es
Priority to EP01972111A priority patent/EP1325739B1/en
Publication of ES2186484A1 publication Critical patent/ES2186484A1/es
Application granted granted Critical
Publication of ES2186484B1 publication Critical patent/ES2186484B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Liposomas encapsulando fármacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. Los liposomas están recubiertos por un lipopéptido compuesto por tres subestructuras: un fragmento lipídico, un oligopéptido activo y un oligopéptido espaciador entre los otros dos fragmentos. Aplicable en la administración intravenosa para el tratamiento de tumores malignos.
ES200002447A 2000-10-10 2000-10-10 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. Expired - Fee Related ES2186484B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES200002447A ES2186484B1 (es) 2000-10-10 2000-10-10 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
JP2002533840A JP4286535B2 (ja) 2000-10-10 2001-10-03 抗癌剤を封入したリポソーム及び悪性腫瘍の治療におけるその使用方法
AU9190401A AU9190401A (en) 2000-10-10 2001-10-03 Liposomes encapsulating anticancer drugs and the use thereof in the treatment ofmalignant tumors
AT01972111T ATE318582T1 (de) 2000-10-10 2001-10-03 Liposomen welche antikanzeröse wirkstoffe verkapseln und deren verwendung zur behandlung von malignen tumoren
AU2001291904A AU2001291904C1 (en) 2000-10-10 2001-10-03 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors
PT01972111T PT1325739E (pt) 2000-10-10 2001-10-03 Lipossomas que encapsulam farmacos anti-cancerigenos e sua utilizacao no tratamento de tumores malignos
PCT/ES2001/000367 WO2002030397A1 (es) 2000-10-10 2001-10-03 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos
DE60117583T DE60117583T2 (de) 2000-10-10 2001-10-03 Liposomen welche antikanzeröse wirkstoffe verkapseln und deren verwendung zur behandlung von malignen tumoren
CA2425271A CA2425271C (en) 2000-10-10 2001-10-03 Liposomes encapsulating anticancerous drugs and use thereof in the treatment of malignant tumours
US10/398,627 US7153490B2 (en) 2000-10-10 2001-10-03 Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors
DK01972111T DK1325739T3 (da) 2000-10-10 2001-10-03 Liposomer, der indkapsler anti-cancerlægemidler og anvendelsen deraf i behandlingen af maligne tumorer
ES01972111T ES2259674T3 (es) 2000-10-10 2001-10-03 Liposomas de encapsulacion de farmacos anticancerosos y utilizacion de los mismos en el tratamiento de tumores malignos.
MXPA03003125A MXPA03003125A (es) 2000-10-10 2001-10-03 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
EP01972111A EP1325739B1 (en) 2000-10-10 2001-10-03 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors
BR0113552-0A BR0113552A (pt) 2000-10-10 2001-10-03 Lipossomas que encapsulam fármacos anticancerìgenos e uso dos mesmos no tratamento de tumores malignos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002447A ES2186484B1 (es) 2000-10-10 2000-10-10 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.

Publications (2)

Publication Number Publication Date
ES2186484A1 ES2186484A1 (es) 2003-05-01
ES2186484B1 true ES2186484B1 (es) 2004-07-01

Family

ID=8495226

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200002447A Expired - Fee Related ES2186484B1 (es) 2000-10-10 2000-10-10 Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
ES01972111T Expired - Lifetime ES2259674T3 (es) 2000-10-10 2001-10-03 Liposomas de encapsulacion de farmacos anticancerosos y utilizacion de los mismos en el tratamiento de tumores malignos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01972111T Expired - Lifetime ES2259674T3 (es) 2000-10-10 2001-10-03 Liposomas de encapsulacion de farmacos anticancerosos y utilizacion de los mismos en el tratamiento de tumores malignos.

Country Status (13)

Country Link
US (1) US7153490B2 (es)
EP (1) EP1325739B1 (es)
JP (1) JP4286535B2 (es)
AT (1) ATE318582T1 (es)
AU (1) AU9190401A (es)
BR (1) BR0113552A (es)
CA (1) CA2425271C (es)
DE (1) DE60117583T2 (es)
DK (1) DK1325739T3 (es)
ES (2) ES2186484B1 (es)
MX (1) MXPA03003125A (es)
PT (1) PT1325739E (es)
WO (1) WO2002030397A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028913B2 (en) 2006-12-29 2018-07-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Liposomal pharmaceutical preparation and method for manufacturing the same

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2004218090A1 (en) * 2003-03-04 2004-09-16 Sosei Co., Ltd. GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
WO2005021012A1 (ja) * 2003-08-29 2005-03-10 Terumo Kabushiki Kaisha ゲムシタビン封入薬剤担体
US20050214286A1 (en) * 2004-01-27 2005-09-29 University Of Southern California Polymer-bound antibody cancer therapeutic agent
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
ES2293753B1 (es) * 2004-04-28 2009-03-16 Lipotec, S.A. Uso de peptidos xikvav en preparacion de composiciones cosmeticas para mejorar la firmeza de la piel mediante el aumento de la adhesion celular.
CN100438855C (zh) * 2006-01-19 2008-12-03 浙江大学 重酒石酸长春瑞滨脂质体及其冻干粉针与制备方法
JP4966084B2 (ja) 2007-04-25 2012-07-04 エスアイアイ・プリンテック株式会社 インクジェットヘッドの駆動方法、インクジェットヘッドおよびインクジェット記録装置
US8067432B2 (en) * 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN103083239B (zh) 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN106955271A (zh) * 2016-01-08 2017-07-18 佛山英特医药科技有限公司 奥沙利铂聚集体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
CA2088975A1 (en) 1990-08-08 1992-02-09 Anthony H. Huang Stable doxorubicin/liposome composition
ES2072223B1 (es) 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRANDT, D.S. et al.: "Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo", JOURNAL OF CELLULAR PHYSIOLOGY, Vol. 153, nº 3, 1991, páginas 614-625. Todo el documento. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028913B2 (en) 2006-12-29 2018-07-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Liposomal pharmaceutical preparation and method for manufacturing the same

Also Published As

Publication number Publication date
EP1325739A1 (en) 2003-07-09
ES2186484A1 (es) 2003-05-01
MXPA03003125A (es) 2004-05-04
BR0113552A (pt) 2003-07-29
ES2259674T3 (es) 2006-10-16
US20050100590A1 (en) 2005-05-12
AU9190401A (en) 2002-04-22
US7153490B2 (en) 2006-12-26
JP4286535B2 (ja) 2009-07-01
ATE318582T1 (de) 2006-03-15
DE60117583T2 (de) 2006-10-05
CA2425271C (en) 2011-04-19
WO2002030397A1 (es) 2002-04-18
AU2001291904B2 (en) 2006-05-11
DK1325739T3 (da) 2006-07-10
DE60117583D1 (de) 2006-04-27
EP1325739B1 (en) 2006-03-01
WO2002030397A9 (es) 2004-05-13
PT1325739E (pt) 2006-07-31
JP2004510811A (ja) 2004-04-08
CA2425271A1 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
ES2186484B1 (es) Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
DK1308168T3 (da) Nye lægemidler mod cancer
BRPI0608297A2 (pt) composições de lipossomos
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
BR0010612A (pt) Vacinas
FI3173073T3 (fi) Liposomeja lääkkeen antamiseen
NO20026255D0 (no) Polymere micelle sammensetninger
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
WO2008096831A1 (ja) 癌の治療剤
ECSP083351A (es) Composiciones farmacéuticas
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AR030281A1 (es) Quimioterapia de combinacion
CO6251231A2 (es) Dispositivo y uso para conservar y poner a disposicion aobleas de medicamento
CY1113488T1 (el) Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας
AR027772A1 (es) Boquilla para un inhalador de material corpuscular
WO2007008858A3 (en) Metered-dose and safety and compliance packaging for systemic anticancer therapy
AR023536A1 (es) Vacunas
UA90493C2 (ru) Альфа-тимозиновые пептиды как адьюванты противораковых вакцин
AR042308A1 (es) Medicamento de administracion transdermica y transmucosica con absorcion mejorada de principios activos
DE60214476D1 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030501

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2186484B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100616